Introduction
Human Factor IX circulates in plasma as a proenzyme of a serine protease, which participates in an early phase of the This paper was presented in part at the 56th session of the American Heart Association, November, 1983, Anaheim, CA (1983 Circulation. 68: 1065A).
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blood coagulation cascade (1) . It is a single chain vitamin Kdependent protein of 416 amino acids (2) and contains 17% carbohydrate by weight (2, 3) . The first 12 glutamic acid residues in the amino terminus of the protein are present as y-carboxyglutamic acid residues (Gla)' and are thought to be involved in Ca2' and phospholipid (PL) binding to Factor IX (1, 4, 5) . The present evidence suggests that during clotting, Factor IX may be activated by Factor XIa requiring Ca2+ (4) (5) (6) , and by Factor VIIa requiring Ca2' and tissue factor (7).
Activation of Factor IX either by Factor XIa or by Factor VIIa involves two steps. In the first step, arginine (Arg)'45-alanine (Ala)'" bond is cleaved, giving rise to a disulfide bond(s) linked two chain intermediate, Factor IXa"2 (2, 6, 8) .
In the second step, Arg'80-valine (Val)'8' bond is cleaved, giving rise to Factor IXa and release of an activation glycopeptide (2, 6, 8) . The primary role of Factor IXa in clotting is to activate Factor X to Factor Xa (1) . The physiological activator of this reaction is believed to be a complex of Factor IXa, Ca2 , PL and thrombin activated Factor VIIIC (1). Factor IXa serves as an enzyme for this reaction, and Ca2 , PL, and activated Factor VIIIC serve as cofactors for this reaction (9) . Factor IXa also binds to antithrombin-III, and the binding occurs through the active site residue, serine (Ser)366, present in the heavy chain of Factor IXa (2, 6) . Factor IXa has also been shown to activate Factor VII to Factor VIIa; this reaction requires Ca2' and PL (10) .
Factor IX serves an important role in coagulation since deficiency of the coagulant activity of this protein causes a hemorrhagic state commonly known as hemophilia-B (Christmas disease). In most of the patients, the deficiency of the clotting activity is due to the absence of Factor IX molecule; however, in 10-30% of the patients the deficiency of the clotting activity is due to the presence of abnormal variants of Factor IX molecule (11-13). The molecular abnormalities in these functionally impaired molecules are just beginning to be investigated. Factor IXzup is a genetic variant with an abnormally high molecular weight and appears to have decreased binding for Ca2l (14) . Another variant of Factor IX, Factor IXChapel Hill, is well characterized. This variant does not undergo normal activation by Factor XIa; during activation only Arg"'0-Val"'8 bond is cleaved (15, 16) . The inability of Factor XIa to cleave Arg'45-Ala14 bond in Factor IXChp1 Hill is due to the substitution of histidine for arginine at position 145 (17) .
In this study we isolate and extensively characterize three variant Factor IX molecules. In initial studies (18, 19) 12 -fold increase in procoagulant activity was observed. Human brain tissue factor was a preparation obtained as described (20) . All other chemicals were of the best commercially available grade.
Proteins. Human Factors IX and X were purified as described earlier (21) . Human Factor VII was purified by the method of Bajaj et al. (22) except that the last step of purification, the preparative polyacrylamide gel electrophoresis was replaced by Sulfopropyl-Sephadex chromatography (23) . Human Factor XI was purified by the procedure of Kurachi and Davie (24) . Factor VIIa (22) , Factor Xa (21) and Factor XIa (5) were prepared as described. Concentrations of purified 3. Bajaj, S. P., S. I. Rapaport, and S. L. Maki, submitted for publication.
proteins were determined spectrophotometrically using EM of 13.4 for Factor XI (24), 11.6 for Factor X (3), and 13.2 for Factor IXN (6). A 13.2 value of E2I was also used for each Factor IX variant protein since the amino acid compositions of Factor IXN and each of the factor IX variant proteins were found to be very similar (Results).
Factor IXN,,,,W (Factor IXN) and each of the variant Factor IX molecules were labeled with 125I by using Bio-Rad Enzymobead reagent as described previously for prothrombin (25) . Radiospecific activities of the preparations were: '251-Factor IXN 3.7 X 109 cpm/mg, 125I-Factor IXBmLE 1.5 X 109 cpm/mg, '251I-Factor IXLB 3.5 X 109 cpm/mg, and 125I-Factor IXLA 3.1 X 109 cpm/mg. '25I-Factor IXN retained 95% of the biological activity of the unlabeled control. Factor VII was labeled with 125I by using Pierce Iodogen reagent. The procedure followed was that outlined in the instruction manual supplied by the company.
Specific activity of the preparation was 1.5 X 109 cpm/mg, and the labeled protein retained -90% of the clotting activity of the nonlabeled control.
Tritium (21) . The clotting assay and the coupled amidolytic assay for Factor VII were performed as outlined by Seligsohn et al. (27) except that the human brain thromboplastin was replaced by rabbit brain thromboplastin (23) . Ox brain prothrombin times were measured as described (18). A value for normal plasma was 41±3 s.
Electrophoresis. Sodium dodecyl sulfate (NaDodSO4) gel electrophoresis was performed according to the procedure of Weber and Osborn (28) . The protein standards used to determine apparent molecular weight have been described (22) . Nondenaturing disc gel electrophoresis was performed according to the procedure of Davis (29) . 3H and 125I radioactivity profiles of NaDodSO4 1-mm gel slices were obtained as described (8) .
Isoelectric focusing. Isoelectric focusing on acrylamide gels was carried out in 9.3 M urea as described earlier for prothrombin (25 (5) . Similarly, the rates of activation of 3H-Factor X were measured from the activation peptide release as outlined by Silverberg et al. (33) . The minor modifications for this assay were also the same as described for Factor IX (5). The concentrations of various reactants in the incubation mixtures are given in the legends to Fig. 3 Activation ofFactor VII by the cleaved normal and variant Factor IX proteins. For studies dealing with the activation of Factor VII and of Factor X, cleaved normal and variant Factor IX proteins were obtained by the incubation of Factor IX preparations (100 ug/ml) with Factor XIa (0.2 ,ug/ml) for 30 min at 37°C. The buffer used was 0.05 M Tris-HCl, 0.15 M NaCI, pH 7.5 containing 5 mM Ca2+. Under these conditions Factor IX proteins were >90% cleaved as examined by NaDodSO4 gel electrophoresis. The cleaved Factor IX proteins were placed on ice and used within 20 min. Since Factor XIa does not activate Factor VII or Factor X, it was not removed from Factor IXa preparations. The activations of Factor VII by the cleaved Factor IX proteins were carried out as described previously (10, 22) . The incubation mixtures contained normal or variant Factor IXa preparations (2.8 Mg/ml), I2'l-Factor VII (2.5 Mg/ml), phospholipid (50 ,M), and Ca2l (5 mM). The buffer used was 0.05 M Tris-HCI, 0.15 M NaCl, I mg/ ml bovine serum albumin (Tris/NaCI/Alb), pH 7.5 and both Factor VII and Factor IXa preparations were treated with an antisera to Factor X (10) to prevent possible activation of Factor VII by trace amounts of contaminating Factor Xa. The incubation temperature was 37°C and 10-,u aliquots were removed at different times and added to 90 ,l of Tris/NaCI/Alb containing 6 mM Na2EDTA. The samples were further diluted with Tris/NaCI/Alb and assayed for Factor VII activity both in the clotting (VIIc) and coupled amidolytic (VIIam) assays. The results were expressed as VIIc/VIIam ratio (10) . Samples were also withdrawn from the incubation mixtures at different times for NaDodSO4 gel electrophoresis and radioactivity profiles of the reduced samples were obtained as described (8) . The fraction of Factor VII present in the activated form was calculated as follows:
-(cpm in unactivated Factor VII peak)/(total cpm in all peaks). Neutralization of an anti-Factor IXN monoclonal antibody by the variant Factor IX proteins. A monoclonal antibody that impairs the coagulant activity of normal Factor IXa through interference with its binding to activated Factor VIIIC, was prepared and purified as described.3 The ability of Factor IX variant proteins to neutralize the inhibitory activity of the antibody was studied as follows: Factor IXN (5 ,ug/ml in Tris/NaCI/Alb) or a mixture of Factor IXN and a variant Factor IX protein (both at 5 Mg/ml) was incubated with an equal volume of various concentrations (0-24 Mg/ml) of monoclonal antibody for 30 min at room temperature. Samples were then placed on ice, diluted as needed and assayed for Factor IX clotting activity.
Isolation of variant Factor IX proteins. Plasma from hemophilia-B patients was obtained by plasmapheresis, with informed consent. The variant Factor IX proteins were isolated by the same method as described for normal Factor IX (21) . Approximately 4-12 liters of plasma was used for each preparation and the steps of purification included adsorption of vitamin K-dependent proteins onto barium citrate, ammonium sulfate fractionation, DEAE-Sephadex chromatography, and heparin agarose affinity chromatography. An electroimmunoassay that used rabbit antisera to normal Factor IX (13) was used to monitor variant Factor IX proteins during isolation.
Results
Purification of variant Factor IX proteins. ALL of the three variant Factor IX proteins behaved very similar to normal Factor IX throughout the entire purification procedure. Fig. 1 shows the elution profile obtained on heparin agarose chromatography when Factor IXBmLE plasma was used as the starting material. Peak A was eluted with 0.02 M citrate, 1 mM benzamidine, pH 7.5, and contained the major fraction, designated H-IIl (21) eluted and fractionated with ammonium sulfate, and chromatographed on the DEAE-Sephadex column as described (22) . Protein in the DEAE-Sephadex fractions containing prothrombin, Factor X and Factor IXBmLE was precipitated by the addition of solid ammonium sulfate to 80% saturation. The sample was dialyzed versus 0.02 M citrate, 1 mM benzamidine, pH 7.5, and applied to the heparin agarose column (2.5 X 45 cm) equilibrated with the same buffer (21) . Approximately 200 mg of protein in 25 ml was applied to the column and 10-ml fractions before and 5-ml fractions after the application of the NaCl gradient were collected. A flow rate of 60 ml/h was maintained throughout. After the application of the sample, the column was washed with the initial buffer. Most of the prothrombin (H-II, peak A) was eluted with this buffer. A linear gradient (using 500 ml of buffer in each chamber) in NaCI (0.0-0.6 M) was then applied (left arrow). A minor fraction of prothrombin (H-I42, peak B) and Factor X (peak C) were eluted in the gradient.
At the completion of the gradient (right arrow), the column was developed with 0.02 M citrate, 0.6 M NaCl, I mM benzamidine, pH 7.5 buffer. Factor IXBmLE (peak D) as monitored by an electroimmunoassay (13) (I18, 19) . To study accurate rates of cleavage of these molecules by a sensitive assay (32), we incorporated tritium into the sialic acid residues of these proteins (26 Fig. 2 (solid 2-mercaptoethanol and subsequently subjected to NaDodSO4 gel electrophoresis. The gels were sliced into 1-mm segments and the radioactivity determined as described previously (8) . The profiles shown are of samples removed at 20 min.
as measured by this method were essentially the same as those observed for normal Factor IX when Factor XIa/Ca2' (Fig. 3 A) or Factor VIIa/Ca2+/tissue factor (Fig. 3 B) Fig. 4 A. As expected, in Fig. 4 B. In contrast with the results obtained with Factor IXaN (Fig. 4 A) , it is apparent from the profiles of Fig. 4 and A, Factor IXaLB.
Results of a typical experiment are presented in Fig. 6 . The incubation mixture contained 125I-Factor VII, Ca2+, PL, an antiserum to Factor X, and activated normal or a variant Factor IX. Activation of Factor VII was determined from the measurements of Factor VIIc/VIIam ratios (Fig. 6 A) and also from the 12II-radioactivity profiles on NaDodSO4 gels (Fig. 6   B) . By both methods, the initial rates of activation of Factor VII were: 100% for Factor IXaN, -0.3% for Factor IXaBmLE, and -5-6% for both Factors IXaL and IXajB.
The ability of the cleaved variant Factor IX proteins to activate Factor X was also investigated both in the absence and presence of thrombin activated Factor VIII. The reaction mixture in the absence of Factor VIII consisted of 3H-Factor X, Ca2', PL, and normal Factor IXa or a variant Factor IXa preparation. Activation of Factor X in this system was very slow for both normal and variant Factor IXa preparations and only approximate rates could be obtained (Table I ). Nonetheless, it was repeatedly observed (three experiments) that Factor X could not be activated by Factor IXaBmLE and the rates of activation of Factor X by Factors IXaLA and IXaLB were greatly reduced (-5-10%) compared with those obtained with Factor IXaN (Table I) .
Reaction mixtures for activation of Factor X in the presence of Factor VIII consisted of 3H-Factor X, Ca2+, PL, thrombin activated Factor VIII/von Willebrand preparation, and normal Factor IXa or a variant Factor IXa protein. Fig. 7 (Fig. 8) . The (14, 15, 35, 36) . Factor lXzvh,, variant has an abnormally high molecular weight (-90,000) and an apparent reduced affinity for Ca2" (14) ; additionally, the variant molecule could not be cleaved by Factor XIa (14) . Factor IXChpe, HiM variant exhibits delayed activation with Factor XIa/Ca2` (15, 16 (35, 36) . In preliminary studies, the low coagulant activity of these variants was attributed to the delayed activation of Factor X in the presence of Factor VIII (35, 36) .
The fifth variant (Factor IX~ente) described in the literature has a markedly prolonged ox brain prothrombin time (37) as does our variant Factor IXBmLE. The defect in Factor IXBmLE is at or around the active site (present study). Whereas, the defect in the Factor IXDvenue appears to be at or around the Factor XIa cleavage site Args80-Val'81 (37).
Hemophilia-B is a heterogenous disorder in which up to approximately one-third of the families possess abnormal Factor IX molecules (1 1-13 ). The plasmas from approximately one-fifth of the families with the abnormal molecules have strikingly prolonged ox brain prothrombin times (13, 38 (42) . It is also possible that the defective catalysis is due to substitution of some other amino acid residue that helps bring the catalytic triad residues (histidine, serine, and aspartate) into close proximity. In contrast with these variants, a virtual absence of catalytic activity in Factor IXBmLE may be due to the substitution of the active site serine itself. Davie and co-workers (2, 6) have shown that the active site residues including histidine, serine, and aspartate are located on the heavy chain, Hp, of normal IXa. We plan to isolate the heavy chains of the cleaved normal and variant proteins using our monoclonal antibody.3 Since there are two methionine residues in the heavy chain (2), we will prepare three CNBr fragments of each of the heavy chains. A comparison of the sequences of the three CNBr peptides obtained from normal and variant heavy chains should provide information about the putative residues essential for normal Factor IXa activity.
